Desmopressin Acetate

American Health Packaging initiated a Class II recall of 1,879 cartons of Desmopressin Acetate Tablets nationwide due to missing desiccants, a critical GMP deviation. This event, terminated in August 2022, underscores the imperative for robust quality control in pharmaceutical packaging. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate supply chain disruptions and ensure product integrity.

Ferring Pharmaceuticals Inc. initiated a Class I recall of 184,325 units of Desmopressin Acetate Nasal Spray due to superpotency. This event, terminated after three years, underscores critical quality control failures and significant patient safety risks. Procurement and regulatory teams must scrutinize supplier agreements and ensure robust quality management systems to mitigate similar supply chain vulnerabilities.